EGFR and lung carcinoma: Interestingly, we also observed in parental PC-9 cells that 24 hours of osimertinib treatment was associated with increased nuclear localisation of YAP1/WWTR1 (with no change in total expression levels, Supplementary Fig. 4e); suggesting that modulation of Hippo signalling is an acute response to EGFR inhibition in EGFR mutant lung cancer and might cause drug resistance (Fig. 2e).